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In spite of differences among human oncogenic DNA vi-
ruses, there are some common characteristics. The viral ge-
nome persists in host cells and expresses latent gene products,
and the strategy of cell transformation is generally the same:
tumor viruses target cell signaling pathways. The goal of on-
cogenic viruses is obvious: to protract cell cycle progression
and protect cells from apoptosis, thus perpetuating the virus
genome. Therefore, the common cellular targets for tumor
virus oncoproteins are the most important transcriptional fac-
tors involved in oncogenesis, such as c-myc, NF-B, AP-1, p53,
and others (62). Because there are innumerable cellular path-
ways that can regulate the transcriptional machinery of the cell,
there are many opportunities for tumor viruses to dysregulate
them to the benefit of the virus. It would not be surprising if
any cell signaling pathway implicated in oncogenesis could be
corrupted by oncogenic viruses.
For several years, the Wnt signaling pathway has been the
object of intense attention in diverse biological areas. The
classic Wnt pathway was initially characterized by its role in
development; later came the realization that dysregulation of
this signal transduction pathway plays an important role in
human tumorigenesis, especially in carcinomas (7, 8, 14, 33, 47,
69). A central effector of the Wnt pathway is -catenin, a
multifunctional protein that was first known as a component of
the cadherin cell adhesion complex (7, 9, 16, 33). Normally, the
level of “free” -catenin in the cytoplasm is tightly regulated by
rapid degradation through the ubiquitin-proteasome system (1,
49, 52). According to the most accepted model, -catenin is
phosphorylated by glycogen synthase kinase (GSK)-3 as a
part of the adenomatous polyposis coli protein (APC)/Axin
complex and is subsequently subjected to ubiquitination and
proteasomal degradation (45, 59). Wnt signaling interrupts the
action of GSK-3 through an unknown mechanism, and thus
-catenin is no longer degraded. Accumulated -catenin trans-
locates into the nucleus, where it forms a complex with the
T-cell factor (TCF)/Lef transcription factor and transactivates
the expression of Wnt targets such as c-myc, cyclin D1, and
others (7, 66).
Recently, a quite different general way to dysregulate this
pathway, namely, through the actions of oncogenic viruses, has
been recognized. Several groups have reported that human
tumor viruses and their products are involved in the activation
of the -catenin/TCF pathway (25, 30, 32, 60, 71). Different
viruses appear to use different mechanisms to activate -cate-
nin. The latency-associated nuclear antigen protein of Kaposi’s
sarcoma-associated herpesvirus dysregulates the GSK-3/
APC/Axin phosphorylation complex by binding to GSK-3
(30). The large T-antigen of the human polyomavirus JC virus
binds directly to -catenin and activates it through an unclear
mechanism (25, 32). The latent membrane protein 2A of Ep-
stein-Barr virus (EBV) activates -catenin through phosphati-
dylinositol 3-kinase/AKT activation, leading to phosphoryla-
tion and inactivation of GSK-3 in epithelial cells (60), a
pathway that was previously implicated in -catenin activation
(23, 31, 35, 72). Finally, in B lymphocytes latently infected with
EBV, -catenin is stabilized, cytoplasmic -catenin is associ-
ated with active deubiquitinating enzymes (DUBs), and the
-catenin/TCF pathway is activated in type III latency but not
in type I (71).
Ubiquitin-proteasome-mediated degradation of -catenin is
the key mechanism for the regulation of -catenin levels in
cells. In general, the degradation of proteins via ubiquitin-
proteasome machinery involves three components: ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2),
and ubiquitin ligases (E3) (19, 39). Phosphorylation of -cate-
nin is essential for the ubiquitination and degradation of
-catenin, which are mediated by the -TrCP ubiquitin ligase
in combination with the Skp1-Cullin1 ubiquitin-conjugating
complex (29, 49, 87). -TrCP1 is a member of the F box- and
WD40 repeat-containing family of proteins that recognizes
-catenin as a substrate for ubiquitination only when it is
phosphorylated at both serine residues in the conserved DSG
XXS motif (49, 87, 88). Targeted disruption of the -TrCP1
gene leads to impaired degradation and thus accumulation and
nuclear translocation of -catenin (61).
Recently, a new, phosphorylation-independent pathway of
-catenin degradation has been uncovered. In this case a dis-
tinct ubiquitin ligase complex, Siah-SIP-Skp1-Ebi, promotes
the degradation of -catenin through a mechanism indepen-
dent of GSK-3-mediated phosphorylation (54, 55). Interest-
ingly, the Siah gene is a p53-inducible gene, and Siah mediates
p53-inducible degradation of -catenin (54, 55). Since each of
the DNA tumor viruses encodes a protein that can interact
with p53 (62) and as a result can inactivate p53 function, this
may be another way for viruses to dysregulate the -catenin/
TCF pathway.
* Corresponding author. Mailing address: Lineberger Comprehen-
sive Cancer Center, The University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599-7295. Phone: (919) 966-5907. Fax: (919) 966-
9673. E-mail: joseph_pagano@med.unc.edu.
5089
It is beginning to emerge that tumor viruses modulate the
ubiquitin-proteasome machinery of host cells for their needs,
mostly on the ubiquitin ligase (E3) level. In some cases the
components of E3 can be encoded by the virus; in other cases
viruses preempt host ubiquitin ligases, redirecting them to a
substrate that normally would not be recognized (6).
Herpes simplex virus-infected cell protein 0 (ICP0) is a
unique example of a viral ubiquitin ligase protein with two
independent E3 sites. The N terminus of ICP0 contains a
RING finger domain that is found in the largest known class of
E3 ubiquitin ligases. The RING domain of ICP0 can induce
the accumulation of polyubiquitin chains in the presence of the
E2 conjugating enzymes UbcH5a and UbcH6 in vitro (12) and
is required for the ubiquitin-dependent degradation of ICP0
substrates in vivo (27, 34). The targets of the RING domain of
ICP0 include promyelocytic leukemia antigen and Sp100, con-
stituents of nuclear structures known as ND10s (17, 28, 65).
The C-terminal region of ICP0 contains a different ubiquitin
ligase domain that does not have a RING finger but that binds
the E2 enzyme UbcH3 (80). UbcH3 is the major E2 enzyme in
the E1/E2/E3 complex that promotes ubiquitination and deg-
radation of cyclin D1 (90). Together with the evidence that
ICP0 can stabilize cyclin D1 without binding to it (56), these
results lead to the attractive hypothesis that the C-terminal
domain of ICP0 acts as a pseudo-E3 ligase, competitively in-
hibiting the proteasomal degradation of cyclin D1 (6).
Other examples of tumor virus-encoded ubiquitin ligases are
the two membrane-bound proteins of Kaposi’s sarcoma-asso-
ciated herpesvirus, MIR1 and MIR2 (21). Both MIR1 and
MIR2 can ubiquitinate major histocompatibility complex class
I chains, which leads not to proteasomal but to endolysosomal
degradation (20, 21).
In contrast, the strategies of human papillomavirus (HPV)
and adenovirus for co-opting the host ubiquitin-proteasome
system are quite different and have an important common
target—the p53 tumor suppressor protein (6). The HPV E6
protein forms a complex with the cellular ubiquitin ligase
E6AP, which leads to the ubiquitination and degradation of
p53 in HPV-infected cells (74, 77, 78). E6AP contains the
C-terminal ubiquitin ligase HECT domain that has been shown
to interact with a number of E2 conjugating enzymes, including
UbcH5, UbcH6, UbcH7, and UbcH8 (43, 44, 70). This is an
interesting situation because the virus product prefers to alter
endogenous substrate specificity; normally, p53 is a target for
MDM2 ubiquitin ligase (38, 42), which belongs to a different,
RING finger-containing, class of ubiquitin ligases (81). Al-
though other targets for E6AP besides p53 have been found
(51, 63), the biological role of E6AP in uninfected cells is still
unclear. Furthermore, the ability of HPV to modulate cell pro-
tein turnover by proteasomal degradation is not restricted to
E6. The HPV E7 protein is involved in ubiquitin-dependent deg-
radation of pRb (13, 37), but the ligase partner of E7 is unknown.
In adenovirus-infected cells the level of p53 is reduced, and
two adenovirus products, E1B 55K and E4orf6, have been
shown to be necessary for the decrease of p53 transcriptional
activity (24, 46, 58, 73). Later it became clear that these ade-
novirus products are involved in forming a specific ubiquitin
ligase complex responsible for p53 ubiquitination and protea-
somal degradation. The assembly of E1B and E4orf6 into a
multiprotein complex containing elongins B and C, Cullin5,
and Rbx1 is required for E1B 55K/E4orf6-dependent p53 ubiq-
uitination and proteasomal degradation (36, 67). It is not clear
which E2 conjugating enzymes are important for the ubiquitin
ligase activity of this complex. UbcH5 was used in experiments
in vitro, but in vivo assays detected UbcH3 in the complex with
E4orf6 (67).
As a conclusion, it is pretty clear that the targeting of cellular
proteins to proteasomal degradation through ubiquitination by
way of viral or cellular ubiquitin ligases is an important aspect
of infection and cell transformation by tumor viruses.
Deubiquitination, as a process counteracting ubiquitination,
has recently received increasing attention. Since the first time
deubiquitinating activity—cleavage of ubiquitin from histone
H2A—was described (2), a huge number of DUBs have been
identified. At least four distinct families of DUBs are now
known. Well-defined classes include ubiquitin-processing pro-
teases (UBP) and ubiquitin carboxyl-terminal hydrolases
(UCH) (18, 22). Recently, two new groups have been charac-
terized: the Jab1/Csn5 and MPN domain-containing proteins
(the JAMM group of hydrolases) (82, 83, 89) and a family of
cysteine proteases that contains an ovarian tumor domain
(OTU) (5, 26). More details regarding the structure of DUBs
and the mechanism of their function can be found in several
excellent reviews (48, 85, 86). For years, the common under-
standing of the functional role of DUBs was limited to remov-
ing monoubiquitin from proteins such as histones or recycling
ubiquitin from polyubiquitinated peptides after proteasomal
degradation. In the last several years, DUBs have also been
implicated in such fundamentally important biological pro-
cesses as cell growth, differentiation, oncogenesis, development,
and regulation of chromosome structure (86), but knowledge of
the specific biologic roles of DUBs has been lacking.
For a long time, the existence of a large number of tissue-
specific DUBs sharing little sequence similarity suggested the
possibility that this class of proteins had a largely unexplored
substrate specificity (18, 22, 84). It is becoming clearer that a
number of proteins regulating cellular mechanisms for ho-
meostasis in all eukaryotes are controlled not only by phos-
phorylation and dephosphorylation but also by ubiquitination
and deubiquitination. The extraordinary importance of DUBs
was shown recently: the herpesvirus-associated ubiquitin-spe-
cific protease (HAUSP) can remove ubiquitin from the p53
tumor suppressor protein and rescue it from degradation, lead-
ing to p53-mediated cell growth suppression (53), and the
tumor suppressor CYLD (which is mutated in individuals with
familial cylindromatosis [10]) turns out to be a DUB that
negatively regulates NF-B signaling (15, 50, 68, 79).
While the ability of tumor viruses to manipulate the ubiq-
uitination system is now appreciated, the question of whether
viral manipulation of the opposite wing of these linked sys-
tems—deubiquitination—holds true remains largely un-
studied. If oncogenic viruses target signaling pathways in a
ubiquitin-dependent manner and DUBs are also important
regulators of these pathways, it would be logical to suggest that
tumor viruses should affect cellular deubiquitinating processes
as well. Consistent with this hypothesis, ICP0 binds HAUSP
(34), a DUB that is important for p53 stabilization (53), thus
adding another route by which a viral product may inactivate
p53. Interestingly, EBV nuclear antigen 1 (EBNA1) also in-
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teracts with HAUSP, and this interaction influences EBNA1
transcriptional activity (40, 41).
Recently, two cytokine-inducible DUBs—DUB-1 and DUB-
2—have been described. These hematopoiesis-specific genes
with unclear function are rapidly induced after cytokine stim-
ulation (3). Interleukin-2-inducible DUB-2 is constitutively ex-
pressed in human T-lymphotropic virus 1 (HTLV-1)-trans-
formed cells (57). This DUB prolongs cytokine-induced
activation of signal transducers and activators of transcription
and suppresses apoptosis following cytokine withdrawal (57).
Since interleukin-2 is constitutively expressed in HTLV-1-in-
fected cells, this may be an example of an oncogenic virus
regulating DUB expression indirectly, through the activation
of another gene.
The idea that a human-oncogenic virus might direct synthe-
sis of its own DUB is an intriguing scenario that has been
examined recently. Adenovirus infection increases deubiquiti-
nating activity in infected cells via the adenovirus proteinase
Avp, which can function as a DUB in vitro and in vivo (4).
Compared with classical DUBs, Avp seems to act as an enzyme
of low specificity, which suggests that this viral DUB might
deubiquitinate different viral and cellular ubiquitinated sub-
strates, none of which is as yet identified (4).
The activity of DUBs in complex samples, such as mamma-
lian cell extracts, has been difficult to examine. A new chem-
istry-based proteomics approach has allowed the detection of
active DUBs with specific, active-site-directed probes against
this group of enzymes (11). Recently it was shown that EBV
immortalization of B cells results in the activation of a set of
DUBs (64). The authors found that in normal B cells the level
of DUB activity is low in general, which is interesting in itself
and somewhat surprising. A relatively similar set of active
DUBs was detected in both EBV-immortalized B cells and in
Burkitt’s lymphoma (BL) cell lines, with higher UCH-L1 or
UCH-L3 activity in BL cell lines (64). Using the same probe
for active DUBs, we have also observed a DUB in two different
EBV-immortalized B-cell lines with the molecular weight of
UCH-L1 as a major specific band (unpublished data). Also
reported was that EBV infection of B cells induced activation
of HAUSP, which was detected in both EBV-positive and
-negative BL cell lines (64). Since HAUSP fulfills an important
step in the stabilization and activation of p53, these results
raise the questions of why either the tumor virus in EBV-
immortalized cells or c-myc translocation in BL cells activates
this DUB and what the possible functional consequence of this
somewhat counterintuitive activation of p53 in transformed
cells might be.
Interestingly, the activity of the FAM DUB, which had pre-
viously been implicated in -catenin stabilization (75), is in-
creased in both EBV-immortalized and BL cells (64). This
observation suggests that -catenin may be stabilized in both
types of cell lines. But according to our results, -catenin is not
stabilized in several BL cell lines, including intensively studied
EBV-positive BL lines (71) and the EBV-negative BL line
DG75 (unpublished data). Since we observed stabilized -cate-
nin in another EBV-negative BL cell line, BJAB (unpublished
data), these contrary observations may indicate the existence
of genetic or cell signaling variations in BL cell lines. Of
course, it should be noted that -catenin is not the only target
of FAM; AF-6 (also called afadin), an actin-binding multido-
main protein which is involved in Ras signaling, is also subject
to FAM-dependent stabilization (76). Our preliminary data
suggest that cytoplasmic -catenin in EBV-infected cells forms
a complex with a DUB with a molecular weight of 34,000, the
size of UCH-L3 (unpublished data), but a biological function
for this association is unknown. Another interesting observa-
tion is that most DUBs identified in EBV-infected cells be-
come detectable after a certain period of time (more than a
month), suggesting that expression (or increase of activity) of
the enzymes is independent of the direct expression of viral
FIG. 1. Human oncogenic DNA viruses use ubiquitination-deubiquitination systems to dysregulate cell signaling pathways. The strategies for
both processes involve recruitment of either cellular or viral enzymes by viral products, in several cases by identified effectors that act on specific
cellular targets.
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latency products. It raises the speculation that EBV might
induce DUBs in an indirect manner, probably through activa-
tion of intermediate messengers. In any event, all of this evi-
dence supports the suggestion that tumor viruses may utilize
deubiquitinating systems as well as ubiquitination to support
their needs, but our knowledge in this area is very limited, and
obviously much more research is needed in the future.
It has become clear that a number of proteins regulating
cellular mechanisms for homeostasis in all eukaryotes may be
controlled by both ubiquitination and deubiquitination and
that oncogenic viruses play a certain role in the dysregulation
of cell signaling pathways that intervene in this system. In
normal cells the balance between the two processes is likely
determined by a dynamic equilibrium and is highly regulated.
Tumor viruses may affect ubiquitination directly, by using their
own ubiquitinating enzymes, or indirectly, by use of endoge-
nous cellular components of the ubiquitin system. The recent
studies of a DUB encoded by an oncogenic virus (4), as well as
the suggestion that a tumor virus can regulate a cell signaling
pathway through deubiquitination (71), raise the same possi-
bility for the deubiquitinating system, and investigations have
begun in this new area of viral functionality (Fig. 1). The
identification of the mechanisms whereby tumor viruses regu-
late the host ubiquitinating-deubiquitinating systems, including
the viral products involved in this regulation, are central as-
pects of continuing studies. The roles of the ubiquitinating and
deubiquitinating machinery in the oncogenic potential of hu-
man tumor viruses seem to be important not only for viral
oncogenesis but probably also for the understanding of viral
function in general.
ADDENDUM IN PROOF
Since acceptance of this paper, Li et al. (M. Li, C. L. Brooks,
N. Kon, and W. Gu, Mol. Cell 13:879–886, 2004) and Cum-
mings et al. (J. M. Cummings, C. Rago, M. Kohli, K. W. Kinz-
ler, C. Lengauer, and B. Vogelstein, Nature 428:486, 2004)
reported that HAUSP can increase p53 proteasomal degrada-
tion through deubiquitination of MDM2. These data might
help to explain why EBV infection induces HAUSP activation.
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